Table 2. BPC3 SNPs associated with overall prostate cancer at PRACTICAL and meta-analysis.
| SNP | Alleles | BPC3 | PRACTICAL | Meta-analysis | |||||
|---|---|---|---|---|---|---|---|---|---|
| OR (95% CI) | p value | OR (95% CI) | p value | OR (95% CI) | p value | phet | I2 (%) | ||
| rs7014346 | A vs G | 1.19 (1.11–1.28) | 1.60 × 10−6 | 1.20 (1.16–1.23) | 3.21 × 10−34 | 1.20 (1.17–1.23) | 3.33 × 10−43 | 0.97 | 0 |
| rs2687720 | A vs G | 1.15 (1.07–1.24) | 3.48 × 10−4 | 1.11 (1.08–1.15) | 9.43 × 10−13 | 1.12 (1.09–1.15) | 1.92 × 10−15 | 0.44 | 0 |
| rs10505477 | C vs T | 0.85 (0.77–0.93) | 4.15 × 10−4 | 0.80 (0.78–0.83) | 5.15 × 10−45 | 0.81 (0.78–0.83) | 5.26 × 10−42 | 0.30 | 6.70 |
| rs10069690 | C vs T | 1.21 (1.08–1.35) | 6.10 × 10−4 | 1.15 (1.12–1.19) | 1.61 × 10−19 | 1.16 (1.12–1.19) | 3.14 × 10−22 | 0.43 | 0 |
| rs2315008 | T vs G | 0.88 (0.82–0.95) | 1.15 × 10−3 | 0.90 (0.87–0.93) | 4.31 × 10−13 | 0.90 (0.87–0.92) | 2.25 × 10−15 | 0.63 | 0 |
| rs4809330 | A vs G | 0.88 (0.82–0.95) | 1.21 × 10−3 | 0.90 (0.87–0.93) | 6.20 × 10−13 | 0.90 (0.87–0.92) | 3.39 × 10−15 | 0.63 | 0 |
| rs2048327 | G vs A | 1.12 (1.04–1.20) | 3.06 × 10−3 | 1.10 (1.07–1.13) | 5.67 × 10−12 | 1.10 (1.08–1.13) | 6.89 × 10−14 | 0.74 | 0 |
| rs9900242 | A vs G | 0.90 (0.84–0.97) | 5.67 × 10−3 | 0.90 (0.87–0.92) | 3.55 × 10−15 | 0.90 (0.87–0.92) | 7.47 × 10−17 | 0.83 | 0 |
BPC3 = Breast and Prostate Cancer Cohort Consortium; OR = odds ratio; PRACTICAL = Prostate Cancer Association Group to Investigate Cancer Associated Alterations in the Genome; SNP = single-nucleotide polymorphism; phet = p value for Cochran's Q statistic for between-study heterogeneity.
Logistic regression was applied in BPC3 and PRACTICAL Meta-analysis was performed under a random-effects model. All ORs are per-copy of the first allele shown in the Alleles column.